Blood Based Biomarkers Market Trends Are Creating New Opportunities For Industry Leaders
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Blood Based Biomarkers Market Expansion From $28.93 Billion In 2026 To $45.5 Billion In 2030
The blood-based biomarkers market has experienced swift expansion in recent years. Its projected value is set to rise from $25.83 billion in 2025 to $28.94 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.0%. Historical growth can be traced to developments in molecular diagnostics, the implementation of cancer screening initiatives, validation efforts for biomarkers, improvements in hospital diagnostic facilities, and an uptick in research funding.
The blood based biomarkers market is anticipated to experience swift expansion in the years ahead, reaching a value of $45.5 billion by 2030 with a compound annual growth rate (CAGR) of 12.0%. This predicted growth in the forecast period is driven by factors such as the expansion of liquid biopsy, the application of AI-powered analytics for biomarkers, the rising need for chronic disease monitoring, the increasing adoption of personalized medicine, and the growth of point-of-care testing. Key trends shaping this forecast period include a greater acceptance of non-invasive diagnostic methods, an extension of precision oncology uses, heightened utilization for early disease identification, growing demand for customized treatment surveillance, and the integration with clinical decision support systems.
Download A Free Sample Report For Comprehensive Market Insights:
Blood Based Biomarkers Market Development Factors: Which Trends Are Supporting Demand?
The anticipated expansion of the blood-based biomarkers market is being driven by the rising prevalence of cardiovascular diseases. These diseases encompass a range of disorders that impact the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. Their increasing occurrence is largely linked to heightened risk factors, including poor dietary habits and growing obesity rates. Through the analysis of measurable substances in the blood, blood-based biomarkers facilitate the diagnosis and monitoring of cardiovascular conditions by offering critical information on disease progression, risk evaluation, and treatment effectiveness. For example, in September 2024, the National Center for Biotechnology Information, a US-based government agency, announced a global health research initiative. This initiative projected a 90% surge in cardiovascular disease rates from 2025 to 2050, with cardiovascular deaths anticipated to hit 35.6 million by 2050. Consequently, the increasing number of cardiovascular disease cases is fueling the growth of the blood-based biomarkers market.
Blood Based Biomarkers Market Segment Analysis: What Are The Major Market Categories?
The blood based biomarkers market covered in this report is segmented –
1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers
2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies
3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications
4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users
Subsegments:
1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions
2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins
3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels
4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells
5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity
Blood Based Biomarkers Market Transformation Trends: Which Innovations Are Driving Change?
Key players in the blood-based biomarkers market are prioritizing technological innovation, specifically the development of highly precise blood biomarker tests that assist doctors in diagnosing Alzheimer’s disease. These high-accuracy tests rely on specific blood-based biomarkers to detect diseases or track health conditions with exceptional precision and dependability. In October 2023, Quanterix, a life sciences firm headquartered in the United States, introduced LucentAD p-Tau 217, a high-accuracy blood biomarker test designed to support physicians in diagnosing Alzheimer’s disease in adults experiencing cognitive decline. The test analyzes phosphorylated tau protein at threonine 217, a biomarker strongly linked to Alzheimer’s pathology, especially amyloid accumulation in the brain. With an accuracy rate exceeding 90%, the LucentAD p-Tau 217 test meets rigorous diagnostic standards and is meant to complement other diagnostic methods, not replace them.
Blood Based Biomarkers Market Leading Companies Driving Competitive Growth
Major companies operating in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG
Access The Complete Blood Based Biomarkers Market Report:
Blood Based Biomarkers Market Regional Analysis And Leading Geography
North America was the largest region in the blood-based biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
